Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01397968 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures
A Phase 2 study, sponsored by SK Life Science.
- Completed
- Registry status
- Phase 2
- Development phase
- 222
- Enrollment target
NCT01397968 is a Phase 2 study that has completed, run by SK Life Science. The registered enrollment target is 222 participants.
The verdict
NCT01397968, a Phase 2 study, has completed, sponsored by SK Life Science.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 222 participants
- Enrollment target
Study Summary
This study is to evaluate the efficacy of YKP3089 in reducing seizure frequency when compared to baseline in subjects with partial onset seizures not fully controlled despite their treatment with 1 to 3 concomitant anti-epileptic drugs. Also to evaluate the safety and tolerability of YKP3089.
Interventions
- DRUG Placebo
- DRUG YKP3089
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 222 participants |
| Start Date | 2011-07-06 |
| Est. Completion | 2021-01-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01397968
The ClinicalTrials.gov registry entry for NCT01397968 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 222 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SK Life Science, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01397968 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01397968 about?
NCT01397968 is a clinical study titled "Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures". This study is to evaluate the efficacy of YKP3089 in reducing seizure frequency when compared to baseline in subjects with partial onset seizures not fully controlled despite their treatment with 1 to 3 concomitant anti-epileptic drugs. Also to evaluate the safety and tolerability of YKP3089.
What is the current status of trial NCT01397968?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 222 participants. The study started on 2011-07-06. Estimated completion is 2021-01-28.
What interventions are being tested in trial NCT01397968?
The interventions under investigation include: Placebo (DRUG), YKP3089 (DRUG).
Who is sponsoring clinical trial NCT01397968?
This trial is sponsored by SK Life Science, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.